ERBB2 and breast carcinoma: No unexpected safety signals were observed.<h4>Conclusion</h4>T-DM1 biosimilar showed outcomes consistent with those reported for the originator in real-world settings, supporting its broader adoption in both early and advanced HER2-positive breast cancer.